PRKAA1 and inflammatory bowel disease: While preclinical studies have suggested that metformin may exert anti-inflammatory and immunomodulatory effects in IBD through AMP-activated protein kinase (AMPK) activation, inhibition of NF-κB signaling, and modulation of gut microbiota, clinical evidence remains scarce.